Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697519 | Cancer Treatment and Research Communications | 2017 | 5 Pages |
Abstract
In this limited case series, our neoadjuvant combined modality regimen was effective and well tolerated. Concurrent PD-1 blockade with radiation therapy that could readily be applied into daily oncology practice is not limited in particular patient subgroups (e.g. BRAFV600-mutant) and may have a better toxicity profile than concurrent immune checkpoint blockade.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Michail Alevizakos, David W. Ollila, Bhishamjit S. Chera, Leslie G. Dodd, Joshua B. Kish, Stergios J. Moschos,